Differently, both CD4+ TCM and TEM, together with CD8+ TCM (but not CD8+ TEM), were all decreased by the treatment of new-onset T1D patients with Alefacept therapy in T1DAL trial, an approach that use the genetically engineered fusion protein targeting and deleting CD2+ T cells (Rigby et al., 2013). The gene discussed is CD8A; the disease is type 1 diabetes mellitus.